TRT Blood Work: Every Lab Test You Need and How Often to Get Them

If you're considering or currently using testosterone replacement therapy, your blood work is the single most important data set you have. It tells you whether your dose is right, whether your body is tolerating the treatment, and whether emerging issues need attention before they become dangerous. Without consistent lab monitoring, TRT is guesswork.

Two major clinical organizations set the monitoring standards that physicians follow: the American Urological Association (AUA) and the Endocrine Society. Both recommend a structured schedule of baseline testing, early follow-up, and ongoing surveillance. This guide translates those guidelines into a practical, comprehensive lab monitoring plan that any man on TRT can understand and track alongside his provider.

Baseline Labs: What to Test Before You Start

Every legitimate TRT protocol begins with a comprehensive blood panel. Starting testosterone without baseline values is medically irresponsible — you need reference points to measure change. The following labs should be drawn before your first injection, application, or oral dose.

Total Testosterone and Free Testosterone

Baseline total testosterone confirms whether you actually meet the biochemical threshold for hypogonadism. Most clinical guidelines define low testosterone as a total serum testosterone below 300 ng/dL measured on two separate mornings. A single low result is not sufficient for diagnosis — levels fluctuate based on sleep, acute illness, stress, and time of day, which is why repeat morning testing is the standard.

Free testosterone, the fraction not bound to sex hormone-binding globulin (SHBG) or albumin, is the biologically active portion. Some men with total testosterone near the lower cutoff have very low free testosterone due to high SHBG. Others have low total testosterone but adequate free levels. Measuring both gives the complete picture.

Complete Blood Count (CBC) with Hematocrit

Testosterone stimulates red blood cell production. Starting testosterone when your hematocrit is already elevated increases the risk of polycythemia, a condition where excessive red blood cells thicken the blood and raise the risk of stroke, heart attack, and blood clots. A baseline hematocrit above 50% is a contraindication for starting TRT according to both the AUA and Endocrine Society guidelines.

The CBC also establishes your baseline hemoglobin, platelet count, and white blood cell count. These parameters are relevant because testosterone influences erythropoiesis and can affect platelet reactivity in some men.

Prostate-Specific Antigen (PSA)

Men over 40, or men over 50 depending on the guideline, should have a baseline PSA before starting TRT. Testosterone does not cause prostate cancer, but it accelerates the growth of existing disease. The AUA recommends discussing the risks and benefits of TRT with patients who have elevated PSA values or suspicious findings on digital rectal examination.

If baseline PSA is elevated, the AUA guidelines recommend urologic evaluation before treatment initiation. This evaluation may include a urology referral, repeat PSA, free-to-total PSA ratio, or prostate imaging depending on the clinical context.

Lipid Panel

Testosterone therapy affects cholesterol metabolism. Studies show that TRT can reduce HDL cholesterol (the protective fraction) by 10-20% in some men. Total cholesterol, LDL, HDL, and triglycerides should be measured at baseline so that changes can be tracked during treatment. Men with borderline cardiovascular risk profiles benefit most from establishing this baseline.

Comprehensive Metabolic Panel (CMP)

The CMP covers liver function (ALT, AST, alkaline phosphatase, bilirubin), kidney function (BUN, creatinine, eGFR), electrolytes, and blood glucose. Liver function is particularly relevant because certain testosterone formulations carry more hepatic burden than others. Oral testosterone undecanoate, for example, is processed differently than injectable esters and has a different safety profile. Kidney function and blood glucose establish important reference values for long-term monitoring.

Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH)

LH and FSH distinguish primary from secondary hypogonadism. In primary testicular failure, LH and FSH are elevated while testosterone is low. In secondary (central) hypogonadism, all three are low. This distinction matters because secondary hypogonadism can signal pituitary problems, prolactin-secreting tumors, or other conditions that require investigation beyond standard TRT. Men with very low testosterone and low LH should be evaluated by an endocrinologist.

For men who plan to preserve fertility, baseline FSH is particularly useful since it reflects your current spermatogenic function before TRT suppresses it.

Estradiol (Sensitive Assay)

Baseline estradiol, measured using a sensitive assay (not the standard assay designed for women), establishes your starting estrogen level. Testosterone converts to estradiol via the aromatase enzyme, and understanding your starting estradiol helps interpret on-therapy changes. Men with high baseline estradiol may experience more pronounced estrogen-related effects when testosterone rises.

Thyroid Panel (TSH, Free T4)

While not explicitly required by TRT monitoring guidelines, TSH and free T4 are recommended because thyroid dysfunction can mimic or worsen hypogonadal symptoms — fatigue, reduced libido, weight changes, and mood shifts. Treating undiagnosed hypothyroidism alongside TRT may reduce the testosterone dose needed for symptom resolution.

Vitamin D and Iron Studies

Vitamin D deficiency is common in men with low testosterone, and some evidence suggests a bidirectional relationship. Iron studies (ferritin, iron, TIBC) are useful because excess or deficient iron can suppress testosterone production. Hemochromatosis, an iron overload disorder, is an established cause of secondary hypogonadism.

Your Monitoring Schedule: When to Recheck Labs

The Endocrine Society guidelines define a clear monitoring timeline. Following this schedule catches problems early and prevents complications from going undetected.

Three to Six Months After Starting

Your first follow-up panel should be drawn at three months. This is the time point at which steady-state testosterone levels are achieved for most formulations. The critical labs at this checkpoint are total testosterone, free testosterone, hematocrit, and PSA for men over 40.

If your testosterone level is not in the target physiological range at three months, your provider may adjust your dose, change your injection frequency, or switch formulations. Dose adjustments require another follow-up lab check at six to twelve weeks to confirm the new level is appropriate.

Hematocrit is monitored closely during this period because the erythropoietic response to testosterone peaks in the first three to six months. A hematocrit rise above 54% typically prompts dose reduction, treatment discontinuation, or therapeutic phlebotomy (blood donation), depending on the clinical context and the treating physician's assessment.

Twelve Months

At the twelve-month mark, repeat the full baseline panel. This comprehensive check confirms that your testosterone levels remain stable, that your hematocrit has plateaued, that your PSA trajectory is acceptable, and that your lipids and liver function have not shifted into concerning territory.

The PSA trend matters more than any single value. A rise of 1.4 ng/mL or more over 12 months warrants urologic consultation even if the absolute value remains within the reference range. This threshold is based on data from the Endocrine Society and AUA guidelines.

Annually Thereafter

Once stable, labs shift to annual monitoring. The core annual panel includes total testosterone, hematocrit, PSA (men over 40), and lipid panel. Your clinician may order the full baseline panel annually or may selectively test based on your individual risk profile and prior results.

Reading Your Testosterone Results: What the Numbers Should Look Like

The goal of TRT is to restore testosterone to the mid-normal physiological range, not to push beyond it. Most guidelines suggest a target total testosterone between 400 and 700 ng/dL, measured at the expected trough time before your next dose.

For men on weekly injections, this typically means drawing blood approximately 7 days after the last injection. For split-dose protocols, your trough will be slightly higher and your peak slightly lower, which is one reason split-dosing is often preferred for laboratory monitoring and for maintaining consistent symptom control.

Free testosterone should fall within the age-adjusted reference range. There is no single universal target because free testosterone depends on your SHBG level and the assay used. Your provider should interpret your free testosterone relative to the laboratory's reference range and your clinical symptom response.

Estradiol on TRT

As testosterone rises, estradiol usually increases proportionally. This is normal and physiologically appropriate. Estradiol is essential for bone health, cognitive function, libido, and cardiovascular health in men. The problem is not a higher estradiol itself, but a disproportionate ratio of estradiol to testosterone that causes symptoms such as breast tenderness, water retention, emotional lability, or erectile dysfunction.

Routine estradiol monitoring is not recommended by all guidelines for asymptomatic men. The AUA notes that estradiol should be checked when patients present with symptoms suggestive of elevated estrogen. However, many TRT providers check sensitive estradiol at follow-up intervals to track the estradiol-to-testosterone ratio and anticipate symptoms before they appear.

Hematocrit Management

Hematocrit rise is the most common adverse effect of TRT that requires intervention. Approximately 5-8% of men on TRT will develop hematocrit above 54% within the first year. Several factors increase this risk: injection-based formulations (especially intramuscular), higher doses, sleep apnea, smoking, high-altitude residence, and pre-existing elevated hematocrit.

If your hematocrit approaches 52%, your provider may lower your dose, switch to transdermal testosterone (which has less erythropoietic stimulation), increase injection frequency with lower individual doses, or recommend therapeutic phlebotomy. Therapeutic phlebotomy is effective but treats the downstream consequence, not the cause, and does not eliminate the need for ongoing hematocrit monitoring.

Men should never ignore hematocrit elevation because it independently increases thrombotic risk. The combination of elevated hematocrit plus cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, family history of clotting events) is a higher-risk profile that warrants closer monitoring and potential dose adjustment.

Lipid Changes to Watch For

Testosterone therapy typically produces a modest reduction in HDL cholesterol — in the range of 0.5 to 3.6 mg/dL, depending on the formulation, dose, and individual. This effect is generally not clinically significant in men with normal baseline lipids. However, men with borderline or low HDL at baseline should be counseled about the potential for further reductions and may benefit from lifestyle interventions to preserve HDL levels.

LDL cholesterol and triglycerides show variable changes. Some men experience modest improvement in triglycerides and LDL, while others see no change or slight worsening. The cardiovascular implications of these changes remain an active area of research. Monitoring your lipid panel annually allows your provider to assess whether the trajectory warrants intervention.

What Can Throw Off Your Lab Results

Several factors can produce misleading lab values that don't reflect your true physiological state. Understanding them prevents unnecessary dose adjustments or treatment changes.

Timing of blood draw. This is the most common source of confusion. If you inject testosterone on Monday morning and draw blood on Tuesday, you're measuring the peak concentration, not your baseline trough. For meaningful comparison to the reference range and to prior results, blood should be drawn at the trough — just before your next scheduled dose. For weekly injections, this means day 7.

Recent illness or acute stress. Cortisol suppresses endogenous testosterone production. Recent systemic illness, surgery, or extreme stress can produce transiently low testosterone readings even in men on TRT, because the assay captures both exogenous and any residual endogenous testosterone. Wait until recovery before rechecking baseline panels.

Supplement use. Biotin supplements (vitamin B7), commonly taken for hair and nails, can interfere with certain immunoassay-based hormone tests leading to falsely elevated or decreased results. If you take biotin-containing supplements, inform your provider and consider discontinuing 48-72 hours before blood draw, depending on the dose. DHEA supplementation elevates both testosterone and estradiol and can obscure TRT lab interpretation.

Lab assay variability. Different laboratories use different testosterone assays with different reference ranges. If you switch laboratories, your results may change even if your actual hormone level hasn't. For consistent tracking over time, use the same laboratory when possible. The CDC runs a Hormone Standardization (HoSt) Program that certifies laboratories for accurate testosterone measurement. Using a HoSt-certified lab is the best way to ensure your results are reliable across time.

Red Flags: Results That Require Immediate Medical Attention

While most TRT lab deviations are manageable, certain values demand prompt evaluation. A hematocrit above 54% is a threshold at which most guidelines recommend pausing or reducing TRT and initiating intervention. Rapid PSA elevation (greater than 1.4 ng/mL increase over 12 months, or absolute PSA above 4.0 ng/mL) warrants urologic referral. Liver enzyme elevations exceeding two to three times the upper limit of normal, particularly in men using oral testosterone formulations, require dose reassessment and hepatology evaluation if persistent.

Severely suppressed LH and FSH are expected during TRT, so these don't indicate a problem in monitored patients. But if LH and FSH remain suppressed and testosterone drops to castrate levels after treatment interruption or discontinuation, permanent hypogonadism may be present, and further endocrine evaluation is needed before treatment decisions are made.

A Simple Monitoring Checklist to Share With Your Provider

Bring this checklist to your next appointment to ensure nothing is missed.

Baseline (before starting TRT): Total testosterone (morning, two separate draws), free testosterone, CBC with hematocrit, PSA, comprehensive metabolic panel (liver function, kidney function, glucose), lipid panel, LH/FSH, sensitive estradiol, TSH, vitamin D.

3-month follow-up: Total testosterone, free testosterone, CBC with hematocrit, PSA (men over 40), CMP, lipid panel, sensitive estradiol (if symptoms or per provider preference).

12-month follow-up: Full baseline panel repeated. Assess PSA trend, hematocrit trajectory, lipid changes, and testosterone target range achievement.

Annual (ongoing): Total testosterone, CBC with hematocrit, PSA (men over 40), lipid panel. Adjust frequency and scope based on your clinical history, risk factors, and prior results.

Your blood work is not a formality, it's the operational dashboard for your hormone health. Tracking these markers consistently lets you and your provider make informed adjustments, catch emerging risks early, and ensure that your TRT protocol delivers results safely. Men who monitor their labs systematically get better outcomes than those who don't.